• 3070 Bristol Pike, Suite 112, Bensalem, PA 19020

  • Call Us: (215) 638-4847 |

    Fax: (215) 638-4867

Inovio Pharmaceuticals, Inc. (NASDAQ: INO)

Case Details

Join The Class Action

This lawsuit is for anyone who acquired securities in Inovio Pharmaceuticals, Inc. (NASDAQ: INO) from October 10, 2023 through December 26, 2025.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by telling investors that the Company would likely receive accelerated approval of its recurrent respiratory papillomatosis treatment, INO-3107, when the Company knew that the FDA would not grant the Company accelerated approval.

On August 8, 2024, after market hours, Inovio released its second quarter 2024 financial results, revealing that it expected to submit the Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (‘FDA”) for its recurrent respiratory papillomatosis “RPR”) treatment, INO-3107, in mid-2025, despite previous claims of a mid-2024 submission, due to a “manufacturing issue” with a component of the Company’s proprietary investigational medical device, CELLECTRA. On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume. Then, on December 29, 2025, Inovio disclosed that the FDA had accepted the INO-3107 BLA on a standard review timeline rather than the accelerated review timeline that the Company touted the prospects of. The Company further stated that it did not plan to seek approval under the standard review timeline and planned to request a meeting with the FDA to discuss pursuing accelerated approval. On this news, the price of the Company’s stock again dropped precipitously on unusually heavy trading volume..

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Inovio Pharmaceuticals, Inc. (NASDAQ: INO) from October 10, 2023 through December 26, 2025 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.